Venous thromboembolism (VTE) remains a big problem for trauma professionals and the patients they take care of.

Every trauma center has some sort of VTE prophylaxis protocol for stratifying risk, prescribing mechanical or pharmacologic prophylaxis, and monitoring effectiveness.

This is all well and good for patients in the hospital. But what happens once they go home? Who needs to continue chemoprophylaxis? For how long? And what product?

These are all tough questions, and are not usually part of the protocol.

Although the authors try to imply that twice daily dosing “may be more effective” than once daily, they do admit that the statistics don’t show that.

Unfortunately, the study design makes it nearly impossible to derive any firm results.

It is a retrospective study designed long after the actual patient care, and does not take into account anything other than rudimentary risk stratification.

Read More